Related StoriesKey part of MRSA vaccine puzzle unearthedUC Irvine Health researchers develop one-step test to detect HCV infectionsNew vaccine candidate shows great promise at fighting respiratory syncytial virusNevertheless, the amount of people coping with HIV is still on the increase. Part of the cause is longer that AIDS patients are surviving, thanks to the expansion of antiretroviral therapy in the developing world, where 200 times as many people are getting it now than were simply eight years ago. But for everyone who begins treatment, two others become contaminated. By 2031 when the epidemic turns 50, about 3.2 million adults will become infected each full year, according to a recently available projection. By the center of the century, there may be 70 million people coping with HIV in Africa only.The study was approved by the institutional review board at the National Tumor Institute and at each of the study centers. Treatment Eligible patients were randomly designated to receive either 45 mg or 90 mg of intravenous daunorubicin per square meter daily for 3 days, as well as intravenous cytarabine infused continuously for 7 days. Bone marrow aspiration and biopsy had been performed on day 12 to 14 of therapy. If residual leukemic blasts were seen, a second induction course was presented with with the same dosage and duration of cytarabine plus 45 mg of daunorubicin per square meter for 3 times. After recovery from induction therapy and before assignment to consolidation therapy, complete remission was confirmed by bone marrow biopsy and aspiration.